ATE313545T1 - Verfahren zur herstellung und reinigung von thiolhaltigen maytansinoiden - Google Patents

Verfahren zur herstellung und reinigung von thiolhaltigen maytansinoiden

Info

Publication number
ATE313545T1
ATE313545T1 AT01926594T AT01926594T ATE313545T1 AT E313545 T1 ATE313545 T1 AT E313545T1 AT 01926594 T AT01926594 T AT 01926594T AT 01926594 T AT01926594 T AT 01926594T AT E313545 T1 ATE313545 T1 AT E313545T1
Authority
AT
Austria
Prior art keywords
sub
maytansinol
hydride
thiol
naal
Prior art date
Application number
AT01926594T
Other languages
English (en)
Inventor
Ravi Vankeepuram Jaganna Chari
Wayne Charles Widdison
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Application granted granted Critical
Publication of ATE313545T1 publication Critical patent/ATE313545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01926594T 2000-08-18 2001-04-26 Verfahren zur herstellung und reinigung von thiolhaltigen maytansinoiden ATE313545T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/641,348 US6333410B1 (en) 2000-08-18 2000-08-18 Process for the preparation and purification of thiol-containing maytansinoids
PCT/US2001/010816 WO2002016368A1 (en) 2000-08-18 2001-04-26 Process for the preparation and purification of thiol-containing maytansinoids

Publications (1)

Publication Number Publication Date
ATE313545T1 true ATE313545T1 (de) 2006-01-15

Family

ID=24571977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926594T ATE313545T1 (de) 2000-08-18 2001-04-26 Verfahren zur herstellung und reinigung von thiolhaltigen maytansinoiden

Country Status (10)

Country Link
US (2) US6333410B1 (de)
EP (1) EP1313738B1 (de)
JP (1) JP4922535B2 (de)
AT (1) ATE313545T1 (de)
AU (1) AU763107B2 (de)
CA (2) CA2678754C (de)
DE (1) DE60116113T2 (de)
DK (1) DK1313738T3 (de)
ES (1) ES2253371T3 (de)
WO (1) WO2002016368A1 (de)

Families Citing this family (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AR030612A1 (es) * 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
US20020156274A1 (en) * 2001-03-16 2002-10-24 Terfloth Gerald J. Process for preparing maytansinol
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
AUPR395801A0 (en) * 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
CZ20033208A3 (en) * 2001-04-26 2004-03-17 Biogen, Inc. Cripto blocking antibodies and uses thereof
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2447695C (en) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2002100431A1 (en) * 2001-06-08 2002-12-19 The Forth Military Medical University A pharmaceutical kit comprising anti-human seminal plasma protein single chain antibody/human carboxypeptidase fusion protein and prodrug
US20090297531A1 (en) * 2001-06-20 2009-12-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1409549A4 (de) * 2001-06-20 2007-10-24 Genentech Inc Zusammensetzungen und verfahren für die diagnose und behandlung von tumoren
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
DE10215336A1 (de) * 2002-03-28 2003-10-23 Schering Ag N-Methyl-Homocysteine und ihre Verwendung sowie Verfahren zu ihrer Herstellung
JP2005525423A (ja) * 2002-05-13 2005-08-25 スミスクライン・ビーチャム・コーポレイション メイタンシノールの調製方法
EP1552002A4 (de) * 2002-06-18 2006-02-08 Archemix Corp Aptamer-toxinmoleküle sowie verfahren zu deren verwendung
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
JP2006502110A (ja) * 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR20060080535A (ko) * 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
EP1651162B1 (de) 2003-05-20 2015-10-21 ImmunoGen, Inc. Verbesserte zytotoxische mittel mit neuen maytansinoiden
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN1833020A (zh) * 2003-06-27 2006-09-13 迪亚德克瑟斯公司 Pro104抗体组合物及其使用方法
US7834155B2 (en) * 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
EA014640B1 (ru) * 2003-07-21 2010-12-30 Иммьюноджен, Инк. Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения
JP2007502278A (ja) * 2003-08-14 2007-02-08 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のための大員環β−セクレターゼ阻害剤
US6890962B1 (en) * 2003-11-25 2005-05-10 Chevron U.S.A. Inc. Gas-to-liquid CO2 reduction by use of H2 as a fuel
NZ551180A (en) * 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
AU2004224925C1 (en) * 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US7678783B2 (en) * 2004-11-17 2010-03-16 Merck Sharp & Dohme Corp. Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
US7951949B2 (en) * 2004-11-23 2011-05-31 Merck, Sharp & Dohme, Corp. Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of Alzheimer's disease
CA2593212A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
US7301019B2 (en) * 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006220621A1 (en) * 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
EP1868647A4 (de) 2005-03-24 2009-04-01 Millennium Pharm Inc Ov064-bindende antikörper und verfahren zu ihrer verwendung
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
ATE535529T1 (de) * 2005-08-09 2011-12-15 Millennium Pharm Inc Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
WO2007056550A2 (en) * 2005-11-08 2007-05-18 Immunogen, Inc. Processes for preparation of maytansinol
EP1806365A1 (de) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
EP2111228B1 (de) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 Domain zur Behandlung von Krankheiten begleitet von unerwünschter Angiogenese
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
AU2008230795B2 (en) 2007-03-27 2014-05-29 Bioassets, Llc Constructs and libraries comprising antibody surrogate light chain sequences
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US20090017140A1 (en) * 2007-07-09 2009-01-15 Peter Koepke Maytenus abenfolia extract and methods of extracting and using such extract
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
US20090035395A1 (en) * 2007-08-01 2009-02-05 Peter Koepke Spondias mombin l. extract and methods of extracting and using such extract
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
EP2195023B1 (de) * 2007-08-29 2018-03-07 Sanofi Humanisierte anti-cxcr5-antikörper, derivate und anwendungsverfahren
US7879369B2 (en) * 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
ES2475201T3 (es) * 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos
PL2242772T3 (pl) * 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
US9446146B2 (en) * 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
US9011864B2 (en) * 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
MA33256B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
JP5863640B2 (ja) 2009-04-29 2016-02-16 バイオ−ラッド ラボラトリーズ インコーポレーティッド 免疫複合体の精製
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
WO2011044563A2 (en) 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
WO2011069074A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
CA2793753C (en) 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2011133555A2 (en) 2010-04-20 2011-10-27 The Research Foundation Of State University Of New York Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
EP2598530A2 (de) 2010-07-29 2013-06-05 Xencor, Inc. Antikörper mit modifizierten isoelektrischen punkten
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
CA2815277A1 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
SI2634194T1 (sl) 2010-10-29 2018-11-30 Perseus Proteomics Inc. Anti-cdh3 protitelo, ki ima visoko kapaciteto internalizacije
EP2640727B1 (de) 2010-11-17 2015-05-13 Genentech, Inc. Alaninylmaytansinol-antikörperkonjugate
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012106368A2 (en) 2011-01-31 2012-08-09 The Regents Of The University Of California Methods for inhibiting prostate cancer
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
EP2717916B1 (de) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-wirkstoffkonjugate
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
AP2014007588A0 (en) 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
DK2766392T3 (da) 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2014533954A (ja) 2011-11-21 2014-12-18 イミュノジェン， インコーポレイテッド Ｅｇｆｒ抗体細胞傷害性薬物複合体による、ｅｇｆｒ療法に耐性である腫瘍の治療方法
US10117932B2 (en) 2011-12-08 2018-11-06 Biotest Ag Uses of immunoconjugates targeting CD138
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
AU2013209512B2 (en) 2012-01-20 2017-08-03 I2 Pharmaceuticals, Inc. Surrobody cojugates
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
IN2015KN00329A (de) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
EP2904089A4 (de) 2012-10-04 2016-05-25 Immunogen Inc Verwendung einer pvdf-membran zur reinigung von konjugaten aus zellbindendem mittel und zytotoxikum
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
CN104530235A (zh) 2012-12-21 2015-04-22 百奥泰生物科技(广州)有限公司 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
CN103333246B (zh) 2012-12-21 2015-09-16 百奥泰生物科技(广州)有限公司 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
CN104688740A (zh) 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
CN103254213B (zh) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
SG11201504920SA (en) 2012-12-27 2015-07-30 Sanofi Sa Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2948478B1 (de) 2013-01-25 2019-04-03 Amgen Inc. Antikörper gegen cdh19 für melanome
ES2829597T3 (es) 2013-02-15 2021-06-01 Perseus Proteomics Inc Anticuerpo humanizado anti-CDH3, conjugado de fármaco del mismo y utilización del mismo
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
MX2015010777A (es) 2013-03-14 2016-04-25 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4.
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP3421495A3 (de) 2013-03-15 2019-05-15 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP3587448B1 (de) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimere proteine
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP2994464B1 (de) 2013-05-10 2020-12-09 University of Pittsburgh - Of the Commonwealth System of Higher Education Behandlung von lungen- und anderen leiden
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
BR112016004450A2 (pt) 2013-09-17 2017-10-17 Genentech Inc métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
JP6463744B2 (ja) 2013-10-08 2019-02-06 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
CR20160156A (es) 2013-10-11 2016-11-01 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
WO2015054659A1 (en) 2013-10-11 2015-04-16 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2927022C (en) 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
AR098743A1 (es) 2013-12-13 2016-06-08 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
WO2015112909A1 (en) 2014-01-24 2015-07-30 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
SG11201606714TA (en) 2014-02-14 2016-09-29 Andrew S Chi Improved methods for the treatment of vascularizing cancers
JP6417421B2 (ja) 2014-02-28 2018-11-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 荷電連結体及び共役体のためのその使用
EP4169944A1 (de) 2014-03-14 2023-04-26 Biomolecular Holdings LLC Verfahren zur herstellung von hybridimmunglobulin mit nichtpeptidylverbindung
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
MX2017001946A (es) 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
MA40539A (fr) 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
CN105585579A (zh) * 2014-10-24 2016-05-18 南京联宁生物制药有限公司 一种化合物及其制备方法以及美登素dm1的制备方法
UY36401A (es) 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
CA2966932A1 (en) 2014-11-19 2016-05-26 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
HK1245171A1 (zh) 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3903826B1 (de) 2014-12-04 2024-05-08 Celgene Corporation Biomolekülkonjugate
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US10722523B2 (en) 2015-03-17 2020-07-28 The Regents Of The University Of California Chemoimmunotherapy for epithelial cancer
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
WO2016149464A1 (en) 2015-03-17 2016-09-22 Regeneron Pharmaceuticals, Inc. Amino acid acylation reagents and methods of using the same
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
BR112017026027A2 (pt) 2015-06-08 2018-08-14 Debiopharm Int Sa combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017025458A1 (en) 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
EP3387013B1 (de) 2015-12-07 2022-06-08 Xencor, Inc. Cd3 und psma bindende heterodimere antikörper
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
EP4656204A3 (de) 2016-04-15 2026-06-03 BioAtla, Inc. Anti-axl-antikörper, antikörperfragmente und deren immunkonjugate und verwendungen davon
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
EP4122958A1 (de) 2016-05-13 2023-01-25 BioAtla, Inc. Anti-ror2-antikörper, antikörperfragmente, deren immunkonjugate und verwendungen davon
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11617799B2 (en) 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
RU2019102008A (ru) 2016-06-28 2020-07-28 Ксенкор, Инк. Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
ES3025461T3 (en) 2017-08-22 2025-06-09 Purdue Research Foundation Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
AU2018374283B2 (en) 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
BR112020017053A2 (pt) 2018-02-21 2020-12-15 Celgene Corporation Anticorpos que se ligam ao bcma e usos dos mesmos
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AU2019262521B2 (en) 2018-05-04 2024-04-18 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
CA3099419A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
FI3817770T3 (fi) 2018-07-02 2026-07-06 Amgen Inc Antigeeniä sitova anti-steap1-proteiini
EP3826625A4 (de) 2018-07-23 2022-08-24 Magenta Therapeutics, Inc. Verwendung von anti-cd5-antikörpermedikamentenkonjugat (adc) in der allogenen zelltherapie
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
EP3693023A1 (de) 2019-02-11 2020-08-12 Sanofi Verwendung von anti-ceacam5-immunkonjugaten zur behandlung von lungenkrebs
KR20210124260A (ko) 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
ES2949511T3 (es) 2019-03-01 2023-09-29 Celgene Corp Preparación de maitansinol
EP3930850A1 (de) 2019-03-01 2022-01-05 Xencor, Inc. Enpp3 und cd3 bindende heterodimere antikörper
EP3956332B1 (de) 2019-04-18 2023-02-22 Indena S.p.A. Diasteroselektives verfahren zur herstellung von thiol- oder disulfidhaltigen maytansinoidestern und zwischenprodukten davon
BR112021022815A2 (pt) 2019-05-14 2021-12-28 Genentech Inc Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
WO2020256546A1 (en) 2019-06-17 2020-12-24 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
CR20220166A (es) 2019-10-18 2022-06-15 Genentech Inc Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
CA3156570A1 (en) 2019-11-05 2021-05-14 Jin Xie Functionally modified maytansinoids and compositions and methods of use thereof
US12473579B2 (en) 2019-11-29 2025-11-18 Microbiopharm Japan Co., Ltd. Method for enzymatically producing maytansinol
BR112022013255A2 (pt) 2020-01-09 2022-09-06 Mersana Therapeutics Inc Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
EP4138925A1 (de) 2020-04-24 2023-03-01 Sanofi Antitumor-kombinationen mit anti-ceacam5-antikörperkonjugaten, trifluridin und tipiracil
CA3181000A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
CN115427082A (zh) 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
BR112022020477A2 (pt) 2020-04-24 2022-11-29 Sanofi Sa Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e cetuximabe
EP4149632A1 (de) 2020-05-14 2023-03-22 Xencor, Inc. Msln und cd3 bindende heterodimere antikörper
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
JP7849358B2 (ja) 2020-11-10 2026-04-21 サノフイ Ｃｅａｃａｍ５抗体－薬物コンジュゲート製剤
EP4305067A1 (de) 2021-03-09 2024-01-17 Xencor, Inc. Cd3 und cldn6 bindende heterodimere antikörper
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
EP4399283A2 (de) 2021-09-06 2024-07-17 Veraxa Biotech GmbH Neue aminoacyl-trna-synthetase-varianten zur genetischen codeerweiterung in eukaryoten
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
AU2022382383A1 (en) 2021-11-05 2024-06-20 Eli Lilly And Company Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
EP4433170A1 (de) 2021-11-18 2024-09-25 Oxford BioTherapeutics Ltd Pharmazeutische kombinationen
DK4186529T3 (da) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
JP2024543916A (ja) 2021-11-25 2024-11-26 ヴェラクサ バイオテック ゲーエムベーハー 遺伝暗号拡張を利用した部位特異的結合によって調製された改良された抗体ペイロード複合体（ａｐｃ）
JP2024545427A (ja) 2021-12-02 2024-12-06 サノフイ Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組み合わせ療法
MX2024006766A (es) 2021-12-02 2024-07-29 Sanofi Sa Prueba de cea para la selección de pacientes en tratamiento del cáncer.
KR20240119102A (ko) 2021-12-08 2024-08-06 유럽피안 몰레큘러 바이올로지 래보러토리 표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
EP4372000B1 (de) 2022-02-15 2026-06-17 Tagworks Pharmaceuticals B.V. Maskiertes il12-protein
KR20250049568A (ko) 2022-07-15 2025-04-11 페온 테라퓨틱스 리미티드 Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도
IL320221A (en) 2022-10-12 2025-06-01 Tagworks Pharmaceuticals B V Strained bicyclo-nonanes
CN120569216A (zh) 2023-01-20 2025-08-29 巴斯夫欧洲公司 稳定型生物聚合物组合物、其制造和用途
EP4673181A1 (de) 2023-03-01 2026-01-07 Sanofi Verwendung von anti-ceacam5-immunkonjugaten zur behandlung von neuroendokrinem krebs mit ceacam5 expression
EP4427763A1 (de) 2023-03-06 2024-09-11 Sanofi Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-vegfr-2-antikörpern und anti-pd1/pd-l1-antikörpern
JP2026509291A (ja) 2023-03-10 2026-03-17 タグワークス ファーマシューティカルス ビー．ブイ． 向上されたｔ－リンカーを有するトランス－シクロオクテン
JP2026511090A (ja) 2023-03-23 2026-04-10 サノフイ 癌治療における患者選択のためのＣＥＡＣＡＭ５ ｍＲＮＡアッセイ
EP4719483A1 (de) 2023-06-05 2026-04-08 Sanofi Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-pd1/pd-l1-antikörpern und anti-ctla4-antikörpern
EP4750750A1 (de) 2023-07-27 2026-06-03 Veraxa Biotech GmbH Hydrophile trans-cycloocten (hytco)-verbindungen, konstrukte und konjugate damit
CN122206462A (zh) 2023-09-15 2026-06-12 巴斯夫欧洲公司 稳定型生物聚合物组合物、其制造和用途
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025169012A1 (en) 2024-02-06 2025-08-14 Sanofi Methods of treating ceacam5-expressing cancers
WO2025174248A1 (en) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release
TW202617187A (zh) 2024-08-22 2026-05-01 荷蘭商泰格沃克斯製藥有限公司 反-環辛烯調配物
WO2026078060A1 (en) 2024-10-08 2026-04-16 Basf Se Tocopherol alkoxylates for biopolymer stabilization
WO2026082894A1 (en) 2024-10-17 2026-04-23 Sanofi Ceacam5 antibody-drug conjugate for use in cancer therapy
US20260109780A1 (en) 2024-10-21 2026-04-23 Sonnet BioTherapeutics, Inc. Docking peptides and related antibody-based drug conjugates
WO2026139575A1 (en) 2024-12-23 2026-07-02 Veraxa Biotech Gmbh Novel tco-functionalized glycan engineered immunoglobulin molecules, novel tco-functionalized saccharide compounds for preparing the same, and novel antibody payload conjugates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2241418A1 (de) 1972-08-23 1974-03-07 S Morris Kupchan Antileukaemische ansamakrolide
US4162940A (en) * 1977-03-31 1979-07-31 Takeda Chemical Industries, Ltd. Method for producing Antibiotic C-15003 by culturing nocardia
JPS53124692A (en) 1977-04-01 1978-10-31 Takeda Chem Ind Ltd Preparation of maytansinol, maytansine, and maytansinol, propionate
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
JPS6010718B2 (ja) 1977-03-31 1985-03-19 武田薬品工業株式会社 メイタンシノ−ル，メイタナシンおよびメイタンシノ−ル・プロピオネ−トの製造法
US4145345A (en) * 1977-12-07 1979-03-20 Research Corporation Chromatographic purification of maytansine
JPS5529972A (en) 1978-08-24 1980-03-03 Takeda Chem Ind Ltd Preparation of maytansinol
JPS5566586A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS57192389A (en) * 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
JP4776843B2 (ja) * 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
US6573074B2 (en) 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
AU2001266853B2 (en) 2000-06-14 2005-02-17 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020156274A1 (en) 2001-03-16 2002-10-24 Terfloth Gerald J. Process for preparing maytansinol
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP2006510349A (ja) 2002-08-08 2006-03-30 スミスクライン・ビーチャム・コーポレイション アンサミトシンの単離および精製方法

Also Published As

Publication number Publication date
USRE39151E1 (en) 2006-06-27
WO2002016368A1 (en) 2002-02-28
JP2004506738A (ja) 2004-03-04
CA2678754A1 (en) 2002-02-28
DK1313738T3 (da) 2006-05-01
EP1313738B1 (de) 2005-12-21
HK1056357A1 (en) 2004-02-13
ES2253371T3 (es) 2006-06-01
JP4922535B2 (ja) 2012-04-25
CA2373554C (en) 2011-02-15
EP1313738A1 (de) 2003-05-28
AU5311801A (en) 2002-03-04
DE60116113D1 (de) 2006-01-26
CA2373554A1 (en) 2002-02-28
AU763107B2 (en) 2003-07-10
US6333410B1 (en) 2001-12-25
CA2678754C (en) 2013-08-27
DE60116113T2 (de) 2006-07-27
EP1313738A4 (de) 2005-01-19

Similar Documents

Publication Publication Date Title
DE60116113D1 (de) Verfahren zur herstellung und reinigung von thiolhaltigen maytansinoiden
JP2004506738A5 (de)
JPS57110395A (en) Method of purifying waste water or sludge of waste water
BRPI0410685A (pt) processos de purificação de 1,3-propanodiol e composições
DE50206163D1 (de) Verfahren zur herstellung von (meth)acrylsäureestern
RO111191B1 (ro) Procedeu pentru prepararea si/sau purificarea acidului clavulanic si intermediar de preparare
UA65568A (en) A process for the production of vinyl acetate
DE69911707D1 (de) Verbessertes Verfahren zur Herstellung von Vinylacetat
HUP9601463A3 (en) Process for the desulfurization of sulfurous acid gas-containing waste gas
WO1998008481A3 (en) Process and apparatus for the production of bi-212 and a use thereof
EP1525044B8 (de) Verfahren zur reinigung von luft, vorrichtung zur reinigung von luft und mit dieser vorrichtung versehenes gebäude
EP0735142A3 (de) Verfahren zur Herstellung von (R)-Styroloxiden
DE50204071D1 (de) Verfahren zur Herstellung von Metallformat-Ameisensäure-Mischungen
DE59813477D1 (de) Verfahren und vorrichtung zur biogasgewinnung
EG21091A (en) Preparation of calvulanate salts
FR2793701B1 (fr) Procede de production d'oxygene gazeux
EP0770626A3 (de) Verfahren zur Reinigung von Thrombomodulin
AU5863196A (en) Method for purifying an inert gas while preparing lower alkyl esters
EP0881208A4 (de) Naphthalindicarbonsäure-teilchen und verfahren zu ihrer herstellung
NZ516235A (en) Method for purification of proteins
AU4858799A (en) Methods of separating catalyst in solution from a reaction mixture produced by oxidation of cyclohexane to adipic acid
ATE238329T1 (de) Verfahren zur reinigung von diosmin
JPS5244051A (en) Filthy water purifying system
ATE275566T1 (de) Verfahren zur herstellung von 1,8-
ATE231125T1 (de) Einfaches verfahren zur herstellung von hochwertigem captropril

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1313738

Country of ref document: EP